Lantheus (NASDAQ:LNTH) Releases Quarterly Earnings Results, Beats Expectations By $0.45 EPS

Lantheus (NASDAQ:LNTH) announced its quarterly earnings results on Thursday. The medical equipment provider reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.45, FiscalAI reports. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The firm had revenue of $389.91 million during the quarter, compared to analysts’ expectations of $355.74 million. During the same quarter in the prior year, the company earned $1.27 EPS. The company’s revenue was up 1.5% compared to the same quarter last year.

Lantheus Stock Down 0.1%

NASDAQ:LNTH traded down $0.09 during midday trading on Friday, reaching $100.61. 1,575,979 shares of the stock traded hands, compared to its average volume of 1,090,931. The stock has a market capitalization of $6.57 billion, a PE ratio of 24.78 and a beta of 0.01. Lantheus has a 12-month low of $50.15 and a 12-month high of $111.86. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.89 and a current ratio of 3.25. The business has a 50-day moving average of $100.27 and a two-hundred day moving average of $92.06.

Analyst Ratings Changes

A number of analysts have weighed in on LNTH shares. CJS Securities lowered Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Mizuho cut Lantheus from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $115.00 to $109.00 in a research report on Tuesday, October 13th. Weiss Ratings downgraded Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, October 15th. Leerink Partners set a $102.50 price objective on Lantheus in a research note on Monday, August 3rd. Finally, Brookline Capital Markets downgraded Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Three analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $107.44.

About Lantheus

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.